Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic
burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct
non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of
$11.5 billion or $921,000 average cost per person. Associated disabilities as mental
retardation, delayed speech development add psychological burden of the disease on the family
as well as economic burden.
Mental retardation is the major problem in children with cerebral palsy. Improving mental
development will have a positive effect on quality of life for the child and his family.
Treating associated impairments (mental retardation) with Cerebrolysin will improve mental
development and quality of life, and will decrease the economic burden in children with
cerebral palsy.